TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03663907

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Telemonitoring
Description: The system (the home tele-healthcare platform) designed jointly by engineers and clinical personal to be able daily automated selfreported symptom and weight, blood pressure and heart rate monitoring. The system allow weekly follow up through videoconferences.~Information from the telemonitoring system is automatically downloaded to a secure Internet site for review by clinicians and nurses daily.
Study: NCT02053610

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: obinutuzumab
Description: 1000 mg obinutuzumab intravenous (IV) infusion, on Days 1 \[first infusion split 100 mg on Day 1 and 900 mg on Day 2 as per protocol amendment\], 8 and 15 in Cycle 1 and Day 1 in Cycles 2-6 (28-day cycles).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rituximab
Description: 375 mg/m\^2 rituximab intravenous (IV) infusion on Day 1 of Cycle 1 (Cycle duration is 28 days) then 500 mg/m\^2 IV infusions on Day 1 of Cycles 2-6.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: chlorambucil
Description: Chlorambucil 0.5 mg/kg orally on Day 1 and 15 of each 28-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chlorambucil
Description: Chlorambucil 0.5 mg/kg orally on Day 1 and 15 of each 28-day cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: chlorambucil
Description: Chlorambucil 0.5 mg/kg orally on Day 1 and 15 of each 28-day cycle
Study: NCT03270800

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CTA control
Description: Sublingual and intradernal application of a mucosal adjuvance, drug product is not yet on the market.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IMX101 vaccine
Description: Sublingual and intradermal application of a vaccine, drug product is not yet on the market.
Study: NCT01985815

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VC/VS stimulation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VC/VS stimulation
Study: NCT00337753

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioral Therapy
Description: 5-weeks of Cognitive Behavioral Therapy

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Wait-list
Description: subjects assigned to wait-list condition for six-weeks
Study: NCT03504345

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prometrium
Description: The intervention will involve delaying the transfer of a frozen-thawed embryo into the uterus to increase the duration of progesterone exposure.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prometrium
Description: The intervention will involve delaying the transfer of a frozen-thawed embryo into the uterus to increase the duration of progesterone exposure.
Study: NCT00374751

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Samarium (153SM)
Description: The Samarium is introduced into the vertebral cavity using a 2-way valve by the radiation oncologist. The cement is then introduced via the same 2-way valve into the vertebral cavity by the neurosurgeon.
Study: NCT03184779

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ski and Snowboard Safety Video
Description: The ski and snowboard safety video (\~10 minutes) includes information on preparation, correct protective equipment use (e.g. helmets), and strategies for speed control and collision avoidance. Focus groups were conducted among parents, students, ski patrol, and ski instructors to inform the content and format of the video. Feedback and suggestions from focus groups were utilized to ensure that the video optimized information uptake from children and adolescents who watch the video. The Health Action Process Approach (HAPA) model was embedded throughout the video to ensure evidence-informed pathways towards positive behaviour change.
Study: NCT02097771

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LMA SupremeTM
Study: NCT02738528

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mental practice and brushing guidance in patients with Parkinson Disease
Study: NCT01798979

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG0634
Description: Each subject will receive multiple oral doses of GLPG0634 (200 mg daily for 7 days) from Days 2 to 8.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Each subject will receive a single oral dose of midazolam (2 mg) on 2 occasions (Days 1 and 8)
Study: NCT01762969

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment modification based on molecular response at 3 months
Description: Patients will be treated with imatinib upon diagnosis of CML. Molecular response will be assessed at 3 months of therapy. Based on molecular response imatinib will be continued or changed to another TKI
Study: NCT02385383

Intervention type: DRUG
Intervention: Iron-III Isomaltoside 1000
Description: Protocol for optimizing preoperative Hb using IV Iron-III Isomaltoside 1000
Study: NCT02097771

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: AuraOnceTM
Study: NCT03110081

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Quadratus lumborum block
Description: Quadratus lumborum (QL) block for open partial nephrectomy.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Epidural analgesia
Description: Epidural analgesia for open partial nephrectomy.
Study: NCT00571116

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Disulfiram
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arsenic trioxide
Description: Given IV
Study: NCT00441038

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: The Back Guide
Description: Education on postural hygiene and handout of The Back Guide

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: The Back Book
Description: Education on active management and Handout of The Back Book

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: The Back Book
Description: Education on active management and Handout of The Back Book

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cardiovascular and general health
Description: Education on cardiovascular and general health

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cardiovascular and general health
Description: Education on cardiovascular and general health

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cardiovascular and general health
Description: Education on cardiovascular and general health
Study: NCT02385383

Intervention type: OTHER
Intervention: Standard Care
Description: Standard Care in a historical control cohort
Study: NCT02855736

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Positive Psychology
Description: Gratitude Journal (Emmons and Stern, 2013)~Every evening, patients have to write down the things they feel grateful about.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (food journal)
Description: Food journal (i.e. alimentary list):~Patients have to write down the list of foods eaten during the day.
Study: NCT00531622

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: saredutant (SR48968)
Description: oral administration, capsules

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: escitalopram
Description: oral administration, capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: escitalopram
Description: oral administration, capsules

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: oral administration, capsules

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: oral administration, capsules
Study: NCT01517204

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Direct laryngoscope (Macintoish laryngoscope)
Description: Direct laryngoscope was used to facilitate the intubation of left-sided DLT.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Trachway(R) intubating stylet
Description: Trachway(R) intubating stylet was used to facilitate the intubation of left-sided DLT.
Study: NCT04476940

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: COVID-19 Breastfeeding Support
Description: Intervention will be implemented by trained prenatal care providers to provide comprehensive exclusive breastfeeding and COVID-19 breastfeeding guideline education and support to study participants.
Study: NCT04029805

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Combination of a plant extract (BSL_EP044) and Lactobacillus BSL_PS6
Description: Each participant will consume 2 capsules daily, in the morning and at night without any restriction in the diet nor in their habits of life.

Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Each participant will consume 2 capsules daily, in the morning and at night without any restriction in the diet nor in their habits of life.
Study: NCT02094898

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: 0.3 mg/kg/hr of ketamine infused for 100 minutes
Study: NCT01982799

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral placebo
Description: placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral placebo
Description: placebo
Study: NCT01432626

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: I-123 radiolabeled metaiodobenzylguanidine cardiac imaging
Description: All subjects will receive an intravenous injection of 10 mCi (370 MBq) of 123I-mIBG. A ±10% tolerance of the nominal dose will be allowed, thus yielding an acceptable dose range of 9 to 11 mCi (333 to 407 MBq). The investigational medicinal product will be administered in a volume of 5 mL (diluted using 0.9% sodium chloride as needed) and injected over 1 to 2 minutes. The patient will have planar and SPECT imaging performed after the dose is administered. This dosing and imaging procedure will be performed during the acute phase and after the patient has recovered cardiac function, approximately 6 weeks later. This means that each study subject will receive a total of 2 doses of I123-mIBG at 2 different time points.
Study: NCT01124097

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eslicarbazepine acetate (BIA 2-093)
Description: Tablets will be used.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eslicarbazepine acetate (BIA 2-093)
Description: Tablets will be used.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eslicarbazepine acetate (BIA 2-093)
Description: Tablets will be used.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablets will be used.
Study: NCT02039648

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rumex acetosa L. extract

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01275599

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: telaprevir
Description: Two 375 mg tablets administered every 8 hours on Day 1 through Day 7, inclusive.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: buprenorphine/naloxone
Description: Buprenorphine/naloxone sublingual tablets or films contain buprenorphine HCl and naloxone HCl dihydrate at a ratio of 4:1 buprenorphine:naloxone (ratio of free bases). In this study buprenorphine/naloxone will be dosed from Day -14 through Day 38, inclusive. From Day -14 through Day -1 all subjects will receive a maximum of 24 mg/6 mg of buprenorphine/naloxone. Subjects will not be permitted to change their dose during the telaprevir co-administration period (Day 1 through Day 7) unless warranted by the investigator's clinical judgment of subject safety. After Day 8, the dose of buprenorphine/naloxone may be adjusted if deemed necessary by the investigator.
Study: NCT04451447

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: The White test uses fat emulsion (SMOFLIPID), for localization of bile leakage.
Description: The White test uses fat emulsion (SMOFLIPID), which is a lipid emulsion with a lipid content of 0.2 grams/mL in 100 mL, 250 mL, and 500 Ml that is normally used for parenteral nutrition, for localization of bile leakage.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Saline test (routine test)
Description: The conventional intra-operative saline test, which involves injecting an isotonic sodium chloride solution through the cystic duct, has been used for detection of leaking points from the transected liver surface.
Study: NCT00703183

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACU-4429
Description: administered as a single dose, orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: matching placebo
Description: administered as a single dose, orally
Study: NCT01306123

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nascobal nasal spray (cyanocobalamin, USP)
Description: Single intranasal administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin B12-ratiopharm N, injection solution
Description: One single intramuscular administration
Study: NCT00648687

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: suck 12.5% dextrose in water 5 minutes before the procedure
Description: Newborns will suck 2 ml of D12.5W 5 minutes before eye exam for ROP
Study: NCT02667106

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RX0041-2
Description: Pharmacokinetic study
Study: NCT02865551

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Foley catheter
Description: Extended bladder catheterization after epidural anesthesia.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Short term catheter
Description: Intermittent catheterization every 4 hours after epidural anesthesia.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epidural anesthesia
Description: Performance of epidural anesthesia by a certified anesthesiologist.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epidural anesthesia
Description: Performance of epidural anesthesia by a certified anesthesiologist.
Study: NCT02790879

Intervention type: OTHER
Intervention: Transition pediatric - adult
Study: NCT00126659

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery
Description: Undergo cytoreductive nephrectomy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery
Description: Undergo cytoreductive nephrectomy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery
Description: Undergo cytoreductive nephrectomy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sorafenib tosylate
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sorafenib tosylate
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sorafenib tosylate
Description: Given orally

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT04636645

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Normal treadmill
Description: Participants will exercise for 25 minutes under low-load walking conditions three times a week for 8 consecutive weeks on the AGT treadmill at a set speed of 3.1 mph at 0-degree incline. For each session, 20% support will be given to participants.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Anti-gravity treadmill with lower limb positive pressure
Description: Participants will be exercised for 25 minutes under normal-load walking conditions three times a week for 8 consecutive weeks on the AGT treadmill at a set speed of 3.1 mph at 0-degree incline. Participants will be blinded to the study groups.
Study: NCT01982799

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral ibuprofen
Description: Ibuprofen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral ibuprofen
Description: Ibuprofen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oral naproxen
Description: naproxen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oral naproxen
Description: naproxen
Study: NCT04636645

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Anti-gravity treadmill with without lower limb positive pressure
Description: Participants will be exercised for 25 minutes three times a week for 8 consecutive weeks on the normal treadmill at a set speed of 3.1 mph at a 0-degree incline. Participants will be blinded to the study groups.
Study: NCT02097186

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Remote ischaemic preconditioning
Description: Ischaemic preconditioning is a phenomenon whereby a brief period of non-lethal ischaemia in a tissue renders it resistant to the effects of a subsequent much longer ischaemic insult. Remote ischaemic preconditioning works on the theory that brief ischaemia in one tissue could confer protection on distant organs.
Study: NCT02980523

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRO-157
Description: PRO-157 (Pazufloxacin 0.06%) Laboratories Sophia S.A. de C.V., ophthalmic solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRO-157
Description: PRO-157 (Pazufloxacin 0.06%) Laboratories Sophia S.A. de C.V., ophthalmic solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRO-157
Description: PRO-157 (Pazufloxacin 0.06%) Laboratories Sophia S.A. de C.V., ophthalmic solution

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vigamox
Description: Vigamox® (Moxifloxacin 0.5%), Alcon Laboratories, S.A. de C.V., ophthalmic solution

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zymar®
Description: Zymar® (Gatifloxacin 0.3%), Allergan, S.A. de C.V., ophthalmic solution

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lagricel Ofteno®
Description: Lagricel Ofteno® Sodium hyaluronate 0.4%, Laboratories Sophia S.A. de C.V., ophthalmic solution

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lagricel Ofteno®
Description: Lagricel Ofteno® Sodium hyaluronate 0.4%, Laboratories Sophia S.A. de C.V., ophthalmic solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lagricel Ofteno®
Description: Lagricel Ofteno® Sodium hyaluronate 0.4%, Laboratories Sophia S.A. de C.V., ophthalmic solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lagricel Ofteno®
Description: Lagricel Ofteno® Sodium hyaluronate 0.4%, Laboratories Sophia S.A. de C.V., ophthalmic solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lagricel Ofteno®
Description: Lagricel Ofteno® Sodium hyaluronate 0.4%, Laboratories Sophia S.A. de C.V., ophthalmic solution
Study: NCT02024295

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ademethionine
Description: ademethionine 1000mg ivgtt qd for 2 weeks, then orally 1000mg bid for 4 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Polyene Phosphatidyl choline
Description: Polyene Phosphatidyl choline 10ml ivgtt qd for 2 weeks, then Polyene Phosphatidyl choline 456 mg tid orally for 4 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ademethionine
Description: after 6 weeks of core treatment stage, then ademethionine 1000mg bid or qd orally for 42 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ademethionine
Description: after 6 weeks of core treatment stage, then ademethionine 1000mg bid or qd orally for 42 weeks
Study: NCT00676845

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: olmesartan medoxomil
Description: dosage form: oral tablet; frequency: daily; duration: 52 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: dosage form: tablet; frequency: daily; duration: 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: olmesartan medoxomil
Description: dosage form: oral tablet; frequency: daily; duration: 52 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: olmesartan medoxomil
Description: dosage form: oral tablet; frequency: daily; duration: 52 weeks
Study: NCT00824330

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Control Phase; Exercise Phase
Description: After the completion of the control phase and at the start of the titration phase of the study, participants will be given pedometers and log books, then contacted on a regular basis to help insure compliance with the goal of walking 10,000 steps per day.
Study: NCT01783340

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Azithromycin capsules
Description: Azithromycin capsules will be administered at each immunization

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin capsules
Description: Azithromycin capsules will be administered at each immunization

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo capsules will be administered at each immunization

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Immunization with falciparum
Description: three inoculations with 5 infected mosquito bites

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Immunization with falciparum
Description: three inoculations with 5 infected mosquito bites
Study: NCT02039245

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CANA/MET XR FDC
Description: Each tablet contains Canagliflozin/extended release Metformin (CANA/MET XR) fixed dose combination (FDC) of 150 mg/1,000 mg, to be taken orally (by mouth)
Study: NCT00577135

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furosemide-Q12 hour bolus
Description: Q12 hours bolus

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furosemide-Q12 hour bolus
Description: Q12 hours bolus

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furosemide-Continuous Infusion
Description: Continuous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furosemide-Continuous Infusion
Description: Continuous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furosemide-Low Intensification
Description: 1x oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furosemide-Low Intensification
Description: 1x oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furosemide-High Intensification
Description: 2.5x oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furosemide-High Intensification
Description: 2.5x oral dose